Patents Assigned to Kineta Two, LLC
-
Patent number: 9163222Abstract: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.Type: GrantFiled: November 14, 2012Date of Patent: October 20, 2015Assignee: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, P Campion Fellin, Christina A Scherer, Tory Hagen, Amy Olson
-
Patent number: 9090947Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: GrantFiled: May 28, 2013Date of Patent: July 28, 2015Assignee: Kineta Two, LLCInventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer, Thierry Guillaudeux
-
Patent number: 8951768Abstract: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.Type: GrantFiled: July 11, 2011Date of Patent: February 10, 2015Assignee: Kineta Two, LLCInventors: Shawn P. Iadonato, Charles L. Magness, P. Campion Fellin, Christina A. Scherer, Tory Hagen, Amy Olson
-
Patent number: 8883477Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: June 14, 2013Date of Patent: November 11, 2014Assignee: Kineta Two, LLCInventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Patent number: 8859251Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: July 1, 2013Date of Patent: October 14, 2014Assignee: Kineta Two, LLCInventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20140037717Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: September 5, 2013Publication date: February 6, 2014Applicant: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, Gary Rosenberg, Christina A Scherer, Thierry Guillaudeux
-
Publication number: 20140005101Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: June 14, 2013Publication date: January 2, 2014Applicant: Kineta Two LLCInventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20140005102Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: July 1, 2013Publication date: January 2, 2014Applicant: Kineta Two LLCInventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Patent number: 8551772Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: GrantFiled: November 22, 2011Date of Patent: October 8, 2013Assignee: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, Gary Rosenberg, Christina A Scherer, Thierry Guillaudeux
-
Patent number: 8486678Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: February 1, 2012Date of Patent: July 16, 2013Assignee: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20130157293Abstract: The invention describes methods for manufacturing oligoadenylate synthetase (OAS) proteins for use as active pharmaceutical ingredients in pharmaceutical compositions. A manufacturing method is described that produces large quantities of concentrated, highly active OAS protein for use in pharmaceutical compositions for the treatment of a variety of diseases including viral infection. Methods for monitoring and validating the manufacturing process are also described.Type: ApplicationFiled: September 6, 2012Publication date: June 20, 2013Applicant: Kineta Two, LLCInventors: MARK E BRANUM, Maralee McVean, Just Justesen, Eric J. Tarcha
-
Publication number: 20130142773Abstract: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.Type: ApplicationFiled: November 14, 2012Publication date: June 6, 2013Applicant: KINETA TWO, LLCInventor: Kineta Two, LLC
-
Publication number: 20120321608Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: May 10, 2012Publication date: December 20, 2012Applicant: Kineta Two, LLCInventors: SHAWN P. IADONATO, Charles L. Magness, Gary Rosenberg, Christina A. Scherer, Thierry Guillaudeux
-
Publication number: 20120258908Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: February 1, 2012Publication date: October 11, 2012Applicant: KINETA TWO, LLCInventors: SHAWN P. IADONATO, CHARLES L. MAGNESS, MARK BRANUM, MARALEE MCVEAN, CHRISTINA SCHERER
-
Patent number: 8192973Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: GrantFiled: November 2, 2006Date of Patent: June 5, 2012Assignee: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, Gary Rosenberg, Christina A Scherer, Thierry Guillaudeux
-
Patent number: 8133710Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: March 30, 2010Date of Patent: March 13, 2012Assignee: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Patent number: 8088907Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: GrantFiled: April 2, 2008Date of Patent: January 3, 2012Assignee: Kineta Two, LLCInventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer, Thierry Guillaudeux
-
Patent number: 8030046Abstract: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.Type: GrantFiled: October 9, 2008Date of Patent: October 4, 2011Assignee: Kineta Two, LLCInventors: Shawn P. Iadonato, Charles L. Magness, P. Campion Fellin, Christina A. Scherer, Tory Hagen, Amy Olson